flipper44/Doc logic,...,
Is there any way you can cut the data where there is not a Dcvax-L advantage over any of the recently studied therapies?
How significant to the medical oncology community do you think the headline will be when Dcvax-L reveals their top line survival data?
Do you foresee NWBO getting any mileage out of their final 108 improving numbers? I have commented on this a while ago. Given the subtle parameters which appear to affect DC efficacy, the mfg enhancement could have been as simple as reducing the additional cellular materials which typically would accompany the DC's, which then means they either reduced the volume of the injections and retained the same number of DC's per injection or allowed the volume to remain constant and increased the number of DC's injected. I am thinking they did the former and the removal of ancillary accompanying cellular materials resulted in increased DC efficacy.
News 
Market Data 
Discover 
